– Study Being Conducted in Collaboration with Investigators at Arizona State University and the Mayo Clinic – SAN DIEGO, August 12, 2019 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced enrollment of the first patient in an investigator-sponsored proof-of-concept clinical trial of IMU-838 …
Immunic, Inc. Reports Second Quarter 2019 Financial Results and Highlights Recent Activity
SAN DIEGO, August 8, 2019 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced financial results for the second quarter ended June 30, 2019 and highlights recent activity. “The April closing of our transaction with Vital Therapies, listing on The Nasdaq Capital Market and capital infusion …
Immunic AG Awarded Research Grant by German Federal Ministry of Education and Research in Support of the InnoMuNiCH Project
SAN DIEGO, August 1, 2019 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that the German Federal Ministry of Education and Research has awarded its subsidiary, Immunic AG, a grant in the amount of up to EUR 653,535 (approximately USD 730,000) in support of the …
Immunic, Inc. to Present at the Canaccord Genuity 39th Annual Growth Conference on August 8
SAN DIEGO, July 30, 2019 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will present at the Canaccord Genuity 39th Annual Growth Conference in Boston on Thursday, August 8, 2019 at 2:30 pm EDT. …
Immunic, Inc. Appoints Sanjay S. Patel, CFA, as Chief Financial Officer
SAN DIEGO, July 16, 2019 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the appointment of Sanjay S. Patel, CFA, as Chief Financial Officer, effective July 15, 2019. Mr. Patel replaces Tamara A. Seymour, who has served as the company’s Interim Chief Financial Officer since …
Immunic, Inc. to Present Previously Unpublished Data Regarding Lead Program, IMU-838, at the GI Inflammatory Diseases Summit in Boston
SAN DIEGO, June 24, 2019 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, announced that Hella Kohlhof, Ph.D., Chief Scientific Officer of Immunic, will present today previously unpublished data regarding the company’s lead program, IMU-838, at the GI Inflammatory Diseases Summit (GIIDS) in Boston. The presentation, entitled, …
Immunic, Inc. Files Financial Statements and Pro Forma Financial Information in Accordance with Previously Completed Stock-for-Stock Exchange Transaction and Provides Corporate Update
– Phase 2 Trial in Relapsing-Remitting Multiple Sclerosis Expected to be the First Efficacy Read-Out of IMU‑838; Top-line Data Anticipated in Q3 2020 – SAN DIEGO, June 21, 2019 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that it has filed an amended Current Report …
Immunic, Inc. to Present Newly Available Preclinical Data for IMU-935 in Poster Presentation at the 2nd Conference on Molecular Mechanisms of Inflammation in Trondheim, Norway
– Results confirm IMU-935 as a potent inverse agonist of RORγt with an IC50 of 24 nM, leading to potent inhibition of Th17 differentiation while allowing normal thymocyte maturation – – In addition to its effect on RORγt, IMU-935 is shown to be a DHODH Inhibitor with an IC50 of 240 nM; both mechanisms act synergistically on the reduction of …
Immunic, Inc. to Participate in Investor and Scientific Conferences in June
Listen to the BMO Conference Webcast SAN DIEGO, May 30, 2019 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced management’s participation in a number of scientific and investor conferences in June: June 3-6: 2nd Conference on Molecular Mechanisms of Inflammation: Hella Kohlhof, Ph.D., Chief Scientific …
Immunic, Inc. to Participate in Upcoming May Conferences
SAN DIEGO, May 9, 2019 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that management will participate in the following conferences in May: May 18-21: Digestive Disease Week® (DDW): Dr. Andreas Muehler, Chief Medical Officer of Immunic, will attend the DDW conference, being held at …